Friday, June 24, 2016

Annexon Biosciences Gets $44M

South San Francisco-based Annexon Biosciences, a biopharmaceuticals firm focused on treatments for neurodegenerative disorders, says it has raised $44M in a Series B funding. The funding was led by New Enterprise Associates, and also included Correlation Ventures, Novartis Venture Fund, Clarus and Satter Investment Management. NEA's Frank Torti has joined the company's board with the funding. Annexon Biosciences is led by Doug Love.